Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Neogenomics Inc (NEO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 732,970
  • Shares Outstanding, K 79,240
  • Annual Sales, $ 244,080 K
  • Annual Income, $ -5,720 K
  • 36-Month Beta 1.06
  • Price/Sales 2.98
  • Price/Cash Flow 20.19
  • Price/Book 4.31

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.51 +8.70%
on 06/28/17
9.34 -0.96%
on 07/17/17
+0.38 (+4.28%)
since 06/23/17
3-Month
7.12 +29.92%
on 05/18/17
9.34 -0.96%
on 07/17/17
+0.74 (+8.70%)
since 04/25/17
52-Week
6.90 +34.06%
on 10/26/16
9.88 -6.38%
on 12/13/16
unch (unch)
since 07/25/16

Most Recent Stories

More News
Zacks.com featured highlights: Live Nation Entertainment, NeoGenomics, Salesforce.com, Paycom Software and Covanta Holding

Zacks.com featured highlights: Live Nation Entertainment, NeoGenomics, Salesforce.com, Paycom Software and Covanta Holding

LYV : 36.63 (-0.62%)
NEO : 9.25 (+0.87%)
PAYC : 70.98 (-1.00%)
CRM : 90.63 (+1.07%)
CVA : 13.70 (+3.01%)
5 Toxic Stocks to Abandon or Play Short for Profit

The high price of the toxic stocks can be attributed to either an irrational exuberance associated with them or some serious fundamental drawbacks in the stock.

LYV : 36.63 (-0.62%)
NEO : 9.25 (+0.87%)
PAYC : 70.98 (-1.00%)
CRM : 90.63 (+1.07%)
CVA : 13.70 (+3.01%)
Best Relative Performance in the Life Sciences Tools & Services Industry Detected in Shares of Qiagen Nv (QGEN, NEO, A, BRKR, TMO)

We looked at the Life Sciences Tools & Services industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength....

A : 60.54 (-1.56%)
TMO : 180.13 (-1.11%)
BRKR : 28.49 (-1.28%)
NEO : 9.25 (+0.87%)
QGEN : 34.19 (-1.27%)
Zacks.com featured highlights: Etsy, Live Nation Entertainment, Salesforce.com, Vertex Pharmaceuticals and NeoGenomics

Zacks.com featured highlights: Etsy, Live Nation Entertainment, Salesforce.com, Vertex Pharmaceuticals and NeoGenomics

ETSY : 14.65 (+1.10%)
LYV : 36.63 (-0.62%)
VRTX : 161.97 (-2.49%)
NEO : 9.25 (+0.87%)
CRM : 90.63 (+1.07%)
5 Toxic Stocks to Discard or Play Short for Profit

If you can pinpoint the toxic stocks accurately, you may gain by resorting to an investing strategy called short selling.

ETSY : 14.65 (+1.10%)
LYV : 36.63 (-0.62%)
VRTX : 161.97 (-2.49%)
NEO : 9.25 (+0.87%)
CRM : 90.63 (+1.07%)
NeoGenomics Reports that its NeoLAB(R) Liquid Biopsy Prostate Test is More Accurate than Conventional Biopsies in Predicting High Grade Prostate Cancer

FT. MYERS, FL--(Marketwired - May 15, 2017) - NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced the presentation of results of a new clinical trial...

NEO : 9.25 (+0.87%)
NeoGenomics Reports that its NeoLAB(R) Liquid Biopsy Prostate Test is More Accurate than Conventional Biopsies in Predicting High Grade Prostate Cancer

FT. MYERS, FL--(Marketwired - May 15, 2017) - NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced the presentation of results of a new clinical trial...

NEO : 9.25 (+0.87%)
Investor Network Invites You to the NeoGenomics First Quarter 2017 Earnings Conference Call and Webcast Live on Wednesday, April 26, 2017

FORT MYERS, FL / ACCESSWIRE / April 25, 2017 / NeoGenomics, Inc. (NASDAQ: NEO) will host a conference call and live webcast to discuss the results of the first quarter 2017, to be held Wednesday, April...

NEO : 9.25 (+0.87%)
NeoGenomics Schedules its Q1 2017 Earnings Release for April 26, 2017

FT. MYERS, FL--(Marketwired - April 14, 2017) - NeoGenomics, Inc. (NASDAQ: NEO) announced today that it plans to release its first quarter 2017 financial results on Wednesday, April 26, 2017.

NEO : 9.25 (+0.87%)
NeoGenomics Schedules its Q1 2017 Earnings Release for April 26, 2017

FT. MYERS, FL--(Marketwired - April 14, 2017) - NeoGenomics, Inc. (NASDAQ: NEO) announced today that it plans to release its first quarter 2017 financial results on Wednesday, April 26, 2017.

NEO : 9.25 (+0.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology...

See More

Support & Resistance

2nd Resistance Point 9.62
1st Resistance Point 9.43
Last Price 9.25
1st Support Level 8.92
2nd Support Level 8.60

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.